论文部分内容阅读
《每日经济新闻》讯国家食药监总局发布通告,要求所有经营、使用单位立即停止销售、使用海南益尔药业有限公司生产的氟哌噻吨美利曲辛片。这是源于2015年底食药监总局组织飞行检查时,发现该公司生产的盐酸氟哌噻吨及其制剂氟哌噻吨美利曲辛片存在质量隐患,其药品生产过程中也发现严重缺陷。检查出的问题包括:其原料药存在原料造假、溶解度不符合质量标准、有选择地使用数据等。然而,部分批次盐酸美利曲辛已用于制剂的生产。目前,17批问题药在召回中,其中还有24553盒在召回途中。海南益尔药业生产的3批盐酸氟哌噻吨(批号:150701、150702、150801)不符
“Daily Economic News” News State Food and Drug Administration issued a circular requiring all businesses, the use of units immediately stop selling, the use of Hainan Yier Pharmaceutical Co., Ltd. production of flupentixol MTV tablets. This is from the end of 2015 CFDA flight inspection and found that the company produced flupentixol hydrochloride and its preparation flupentixol MTV tablets there quality problems, the drug production process also found serious flaws . Check out the problems include: the existence of the raw material counterfeit raw materials, the solubility does not meet the quality standards, the selective use of data. However, some batches of melitracine hydrochloride have been used in the manufacture of formulations. Currently, 17 batches of prescription drugs are being recalled, of which 24,553 are in the process of being recalled. Hainan Yier pharmaceutical production of three batches of flupenthixol hydrochloride (batch number: 150,701,150,702,150,801) does not match